Archive | November, 2015

LSN Wishes You A Happy Thanksgiving And A Fruitful Fundraising Campaign

25 Nov

By Dennis Ford, Founder & CEO, LSN 

dennis-websit

This Thanksgiving, we’d like to say thank you for all our Next Phase readers, LSN platform subscribers, RESI attendees and all our friends in the life science investment and entrepreneurship communities. We’re grateful for your support, and we hope to support your success in turn during the year to come.

As is LSN’s Thanksgiving tradition, we’re serving up the 10 most recent life science investment mandates gathered by LSN Research. These mandates show the breadth of coverage that LSN has among life science investors, with investors including international PE firms, expert regional VCs, disease-focused nonprofits, cross-border funds, and family offices. If one of these investors is a fit for your opportunity, we’d love to hear from you.

Click on the mandates below to see what’s cooking in the rest of the world

  1. Cross-Border VC Seeks PMA & 510k Medical Devices
  2. Family Office Medtech Fund Interested in Dental, Aesthetics and Mobile Tech
  3. VC Invests in Technology Platforms in Medtech & Lab Equipment
  4. Southwest VC Invests in Diagnostics, HCIT, Devices & Enabling Technologies
  5. VC Invests in Medtech & HCIT Hospital Solutions in NoCal
  6. Foundation Invests in Cancer Cures Worldwide
  7. Asia VC Invests in Pharmaceuticals & Medtech in the USA
  8. PE Firm Seeks Healthcare Opportunities in India
  9. VC Invests in HCIT, Medical Devices and Diagnostics in Europe
  10. Merchant Bank Seeks Strategic Medtech Opportunities for China Expansion

RESI SF Panel Annoucement: Big Pharma

25 Nov

By Lucy Parkinson, Director of Research, LSN

One of the key shifts in the life science product development landscape in recent years is that big pharma companies are increasingly looking outward for innovation. Pharma corporate development groups are deploying an array of means to source, evaluate and invest in assets discovered or developed by biotech entrepreneurs.

At RESI San Francisco, the Big Pharma panel will explore the shifting dynamic between big pharma and small biotechs. What can you expect from a pharma company’s evaluation process, and what can you do to position your startup to make a deal?  Panelists will answer these questions and provide their advice on how entrepeneurs can take align themselves with the firms that they represent.

Moderated by Kevin Lynch, Vice President, Scientific Assessment, AbbVie, the panelists are:

If you’d like to hear this panel live at RESI and meet with investors from the pharma world and beyond, you can register for RESI San Francisco now.

RESI-San-Francisco-2016

Hot Life Science Investor Mandate 1: Cross-Border VC Seeks PMA & 510k Medical Devices

25 Nov

A venture capital and private equity firm with offices in Israel and Massachusetts has historically invested in in very early stage companies in therapeutics and diagnostics, but now is moving to mid-stage to later stage companies, primarily in medical devices. While the firm has made several lead investments, the firm typically co-invests, seeking partners with large USA private equity funds to make co-investments at $20 million and upwards. The firm currently manages a $120 million fund, and looks to make 2-3 investments within the next year. The firm is open to companies based in the USA, Europe, Israel, and Canada.

While having made investments in therapeutics and diagnostics in the past, the firm now focuses on innovative medical devices. The firm is open to 510K and PMA devices, as well as all indications. The firm prefers to see later stage post-product technology with proven clinical data, and may be interested in companies in clinical stages close to commercialization. The firm is also open to lab equipment and drug development enabling technology.

The firm requires companies to have an established management team, though will also help fill the team, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

%d bloggers like this: